SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
183Novartis still sees sense in Roche merger-paper Tuesday November 19, 6:36 am ET keokalani'nui-11/19/2002
182Either that, or there was some really foul language in the original.nigel bates-11/18/2002
181<i>a) [*] shall not [*] with [*] or [*] any [*] a [*] or [*] and/or [*] foBiomaven-11/18/2002
180Not enough NCEs and innovation....... Message 18245875scaram(o)uche-11/18/2002
179R licensed whole epothilone program and any analogues that could be produced by keokalani'nui-11/18/2002
178Despite this being the most heavily redacted license agreement I have ever seen,tuck-11/18/2002
177And don't miss the combined Roche/kosan development plan fully laid out in Ekeokalani'nui-11/17/2002
176and, lending further clarity....... <i>(a) [*] shall not [*] with [*] scaram(o)uche-11/17/2002
1751.43 “[*]” means (i) any [*] or [*] on which [*] of [*] or [*] of [*] is a [*scaram(o)uche-11/17/2002
174Roche license. Haven't checked it out. sec.govkeokalani'nui-11/17/2002
173<Kosan Signs Agreements with NCI to Clinically Develop Geldanamycin Analogs&gBiomaven-11/14/2002
17211/12/2002 -- Scientists at the University of Pennsylvania have averted the onsekeokalani'nui-11/13/2002
171As the link I posted doesn't seem to be working, here's the bulk of the rkrw-11/7/2002
170They could only do their best. sigh.... :-)rkrw-11/6/2002
169>> I hope Adams Harkness has it right << Wheeeeeeeeeeeeeee! (You dscaram(o)uche-11/6/2002
168I hope Adams Harkness has it right: firstcalladvantage.com "In additionrkrw-11/6/2002
167more guidance!! "a very good deal" (must be at least 95%)scaram(o)uche-11/6/2002
166royalty guidance!!!!! "nice" :-)scaram(o)uche-11/6/2002
165Had you heard first bms candidate may have slipped a bit, potentially putting x8keokalani'nui-11/4/2002
164Blood 2002 Oct 15;100(8):3041-4 BCR-ABL point mutants isolated from patients wscaram(o)uche-11/4/2002
163>> I wonder if this is the announcement of "proof of principle, validscaram(o)uche-11/4/2002
162Near as I can tell, K's geldanamycin program did not start until 1Q02. Starkeokalani'nui-11/4/2002
161Kosan Signs Agreements with NCI to Clinically Develop Geldanamycin Analogs Mondascaram(o)uche-11/4/2002
160Kosan Biosciences Reports Third Quarter and Nine Month Financial Results Thursdamopgcw-10/24/2002
159Kosan/JNJ patent issues....... l2.espacenet.com Ketolide antibacterials Patescaram(o)uche-10/20/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News